Search results for " Ly"

showing 10 items of 2487 documents

Onko persoonana oleminen tärkeää?

2007

konstituutioeksistenssiBaker Lynne Rudderajallinen identiteettipersoonaidentiteettiOlson Ericensimmäisen persoonan perspektiivi
researchProduct

First evidence of antimicrobial activity of neurotoxin 2 from anemonia sulcata (Cnidaria)

2014

International audience; We investigated the antibacterial activity of Anemonia sulcata (Cnidaria, Anthozoa) tentacle and body acidic extracts. Biochemical purification consisted of first step on solid phase Sep-Pak C8 column followed by several HPLC runs on C18 column using different conditions. Anti-Micrococcus lysodeikticus activity has been detected in 40 % acetonitrile fractions. The resulting purified molecule from tentacles had a molecular mass determined by MALDI-TOF mass spectrum of 4946,299 Da and has been completely sequenced. Its aa sequence revealed identity with the Neurotoxin 2 (ATX-II), a Na + channel blocking toxins. Consequently, ATX-II appeared to display a dual role as to…

lcsh:Biology (General)antimicrobial peptideMicrococcus lysodeikticusneurotoxin[SDU.STU.HY]Sciences of the Universe [physics]/Earth Sciences/Hydrologylcsh:QH301-705.5antimicrobial peptide; Anemonia sulcata; ATX II; neurotoxin; Micrococcus lysodeikticusATX IIAnemonia sulcata
researchProduct

Plasma Viscosity and NLR in Young Subjects with Myocardial Infarction: Evaluation at the Initial Stage and at 3 and 12 Months

2018

In the “Sicilian study on juvenile myocardial infarction,” we had evaluated plasma viscosity (PV) and neutrophil/lymphocyte ratio (NLR) in patients with acute myocardial infarction (AMI) at the age of ⩽45 years. Now, we examined the relationship between these 2 parameters in 120 subjects (109 men and 11 women) aged ⩽45 years with recent AMI. The patients were classified according to the number of cardiovascular risk factors, the electrocardiographic criteria (ST-segment elevation myocardial infarction [STEMI] or non-ST-segment elevation myocardial infarction [NSTEMI]), and the extent of coronary stenosis, evaluated with coronary angiography. On fasting venous blood, we measured PV at the sh…

lcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtySettore MED/09 - Medicina Internabusiness.industryLymphocytefungimedicine.diseaseneutrophil lymphocyte ratiomedicine.anatomical_structurelcsh:RC666-701Internal medicinecardiovascular systemCardiologyMedicineplasma viscosityIn patientcardiovascular diseasesMyocardial infarctionjuvenile myocardial infarctionStage (cooking)Cardiology and Cardiovascular MedicinebusinessPlasma viscosityOriginal ResearchClinical Medicine Insights: Cardiology
researchProduct

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma

2019

ABSTRACT The oncoantigen nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces cellular and humoral immune responses in patients with NPM-ALK-positive anaplastic large cell lymphoma (ALCL). We characterize the NPM-ALK-specific T-cell responses in a cohort of pediatric and adolescent ALCL-patients in remission without Human Leucocyte Antigen (HLA)-preselection. First, we assessed NPM-ALK-reactive T-cell responses and their HLA-class I restriction in patients by using dendritic cells (DCs) transfected with in vitro transcribed (IVT) NPM-ALK-RNA for CD8 (n = 20) or CD3 (n = 9) T-cell stimulation. NPM-ALK-specific T-cells were detected in twelve of 29 patients (nine of 20 with CD8-selected…

lcsh:Immunologic diseases. Allergy0301 basic medicineALK-Positive Anaplastic Large Cell LymphomaT cellImmunologylcsh:RC254-282IFN-γ ELISPOT03 medical and health sciences0302 clinical medicineImmune systemimmune system diseaseshemic and lymphatic diseasesmedicineImmunology and AllergyIn patientNPM-ALKImmune responseAnaplastic large-cell lymphomaOriginal Researchintegumentary systemKinasebusiness.industryT-cellslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseALCL3. Good healthLymphomaOncoantigen030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchlcsh:RC581-607businessOncoImmunology
researchProduct

Reciprocal influence of B cells and tumor macro and microenvironments in the ApcMin/+ model of colorectal cancer

2017

One of the most fascinating aspects of the immune system is its dynamism, meant as the ability to change and readapt according to the organism needs. Following an insult, we assist to the spontaneous organization of different immune cells which cooperate, locally and at distance, to build up an appropriate response. Throughout tumor progression, adaptations within the systemic tumor environment, or macroenvironment, result in the promotion of tumor growth, tumor invasion and metastasis to distal organs, but also to dramatic changes in the activity and composition of the immune system. In this work, we show the changes of the B-cell arm of the immune system following tumor progression in the…

lcsh:Immunologic diseases. Allergy0301 basic medicineColorectal cancerImmunologySpleenintestinal cancerBiologylcsh:RC254-282Metastasis03 medical and health sciencesImmune systemPeritoneummedicineImmunology and Allergyapcmin/+ miceApcMin/+mice; B lymphocytes; IgA; IL-10; intestinal cancer; Immunology and Allergy; Immunology; OncologyB lymphocyteApcMin/+micelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePhenotypeInterleukin 10030104 developmental biologymedicine.anatomical_structureOncologyTumor progressionIL-10Immunologyb lymphocyteslcsh:RC581-607IgAOncoImmunology
researchProduct

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study

2017

IF 7.719; International audience; Introduction: Some studies have suggested that baseline tumor-infiltrating-lymphocytes (TILs), such as CD8+ and FoxP3+ T-cells, may be associated with a better prognosis in colorectal cancer. We sought to investigate modulation of the immune response by preoperative radiotherapy (preopRT) and its impact on survival in locally advanced rectal cancer (LARC). Materials & Methods: We analyzed data for 237 patients with LARC who received RT. Density of TILS (CD8+ and FoxP3+) in intraepithelial (iTILs) and stromal compartments (sTILs) were evaluated from surgery pathological specimens and biopsies performed at baseline. The primary endpoint was to assess the impa…

lcsh:Immunologic diseases. Allergy0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentImmunology[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenalcsh:RC254-282radiation therapy[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointImmunology and Allergyrectal cancertranslational studyOriginal ResearchUnivariate analysisbusiness.industryTumor-infiltrating lymphocytesDose fractionationFOXP3hemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease3. Good healthRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesistumor-infiltrating lymphocyteslcsh:RC581-607businessAdjuvant
researchProduct

Trial Watch: Adoptively transferred cells for anticancer immunotherapy

2017

IF 7.719; International audience; Immunotherapies aimed at strengthening immune effector responses against malignant cells are growing at exponential rates. Alongside, the impressive benefits obtained by patients with advanced melanoma who received adoptively transferred tumor-infiltrating lymphocytes (TILs) have encouraged the scientific community to pursue adoptive cell transfer (ACT)-based immunotherapy. ACT involves autologous or allogenic effector lymphocytes that are generally obtained from the peripheral blood or resected tumors, expanded and activated ex vivo, and administered to lymphodepleted patients. ACT may be optionally associated with chemo- and/or immunotherapeutics, with th…

lcsh:Immunologic diseases. Allergy0301 basic medicinePD-L1Adoptive cell transferBreakthrough therapymedicine.medical_treatmentImmunology[SDV.CAN]Life Sciences [q-bio]/CancerReviewBiologycytotoxic T lymphocytelcsh:RC254-282CD19[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineAntigenPD-L1PD-1medicineImmunology and AllergyCytotoxic T cellNK cellchimeric antigen receptorImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChimeric antigen receptor3. Good healthimmune checkpoint blockers030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologybiology.proteinlcsh:RC581-607
researchProduct

A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets.

2018

International audience; NKp46 (CD335) is a surface receptor shared by both human and mouse natural killer (NK) cells and innate lymphoid cells (ILCs) that transduces activating signals necessary to eliminate virus-infected cells and tumors. Here, we describe a spontaneous point mutation of cysteine to arginine (C14R) in the signal peptide of the NKp46 protein in congenic Ly5.1 mice and the newly generated NCR(B6C14R) strain. Ly5.1(C14R) NK cells expressed similar levels of Ncr1 mRNA as C57BL/6, but showed impaired surface NKp46 and reduced ability to control melanoma tumors in vivo. Expression of the mutant NKp46(C14R) in 293T cells showed that NKp46 protein trafficking to the cell surface …

lcsh:Immunologic diseases. Allergy0301 basic medicineSignal peptideintracellular traffickingImmunologyCellCongenicinnate lymphoid cellsBiologymedicine.disease_causelcsh:RC254-28203 medical and health sciences0302 clinical medicinemedicineImmunology and Allergyddc:610congenic miceReceptorOriginal ResearchMutationEndoplasmic reticulumInnate lymphoid cellHEK 293 cellslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCell biology030104 developmental biologymedicine.anatomical_structureOncologyactivation receptors[SDV.IMM]Life Sciences [q-bio]/Immunologylcsh:RC581-607030215 immunology
researchProduct

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

2018

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to improve with the incorporation of this new class of agents with current MM therapies. However, both antigens are also expressed on other normal tissues including hematopoietic lineages and immune effector cells, which may limit their long-term clinical use. B cell maturation antigen (BCMA), a transmembrane glycoprotein in the tumor necrosis factor receptor superfamily 17 (TNFRSF17), is expressed a…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.drug_classT-Lymphocytesmedicine.medical_treatmentImmunologyReceptors Antigen T-CellT-Cell Antigen Receptor Specificitymonoclonal antibody drug conjugateReviewAntibodies Monoclonal HumanizedMonoclonal antibodyImmunotherapy Adoptivebi-specific antibody03 medical and health sciences0302 clinical medicineAntigenSignaling Lymphocytic Activation Molecule FamilyAntibodies BispecificmedicineAnimalsHumansImmunology and AllergyElotuzumabbusiness.industrySLAMF7B-Cell Maturation AntigenAntibodies MonoclonalImmunotherapychimeric antigen receptor T cellADP-ribosyl Cyclase 1Chimeric antigen receptormultiple myelomaB-cell maturation antigen030104 developmental biologymonoclonal antibody030220 oncology & carcinogenesisProteasome inhibitorCancer researchImmunotherapytargeted immunotherapylcsh:RC581-607businessmedicine.drugFrontiers in Immunology
researchProduct

Deciphering the Roles of Innate Lymphoid Cells in Cancer

2019

Cancer is a complex disease and the role played by innate lymphoid cells (ILCs) in cancer development has begun to be uncovered over recent years. We aim to provide an exhaustive summary of the knowledge acquired on the role of ILCs in cancer. ILCs are classified into 3 different categories, ILC1s, ILC2s, and ILC3s, each encompassing specific and unique functions. ILC1s exhibit NK cells characteristics and can exert anti-tumor functions, but surprisingly their IFNγ production is not associated with a better immune response. In response to TGF-β or IL-12, ILC1s were shown to exert pro-tumor functions and to favor tumor growth. ILC2s role in cancer immune response is dependent on cytokine con…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.medical_treatmentMDSCImmunologyinnate lymphoid cellsContext (language use)ReviewBiology03 medical and health sciences0302 clinical medicineImmune systemImmunityNeoplasmsEosinophil activationcytokinemedicinecancerAnimalsHumansImmunology and AllergyLymphocytesInnate lymphoid cellCancerImmunotherapymedicine.diseaseImmunity Innate030104 developmental biologyCytokineCancer researchimmunotherapylcsh:RC581-607030215 immunologyFrontiers in Immunology
researchProduct